-
EP4382135
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4382135
| EP4382135 - CANCER-SPECIFIC TRANS-SPLICING RIBOZYME AS GENE THERAPY PRODUCT COMBINED WITH RADIOTHERAPY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 10.05.2024 Database last updated on 29.10.2024 | |
| Former | The international publication has been made Status updated on 10.02.2023 | Most recent event Tooltip | 11.10.2024 | Change: Validation states | published on 13.11.2024 [2024/46] | 11.10.2024 | Change - extension states | published on 13.11.2024 [2024/46] | Applicant(s) | For all designated states RZNOMICS INC. 327, Software ICT Building Dankook University 152, Jukjeon-ro Suji-gu Yongin-si, Gyeonggi-do 16890 / KR | [2024/24] | Inventor(s) | 01 /
LEE, Seong-Wook Seoul 02780 / KR | 02 /
HAN, Seung Ryul Yongin-si, Gyeonggi-do 16919 / KR | 03 /
PARK, Hee Chul Seoul 06355 / KR | 04 /
CHOI, Changhoon Seongnam-si, Gyeonggi-do 13600 / KR | 05 /
SHIN, Sungwon Seoul 05841 / KR | [2024/24] | Representative(s) | De Clercq & Partners Edgard Gevaertdreef 10a 9830 Sint-Martens-Latem / BE | [2024/24] | Application number, filing date | 22853581.1 | 08.08.2022 | [2024/24] | WO2022KR11774 | Priority number, date | KR20210103814 | 06.08.2021 Original published format: KR 20210103814 | KR20220098089 | 05.08.2022 Original published format: KR 20220098089 | [2024/24] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023014206 | Date: | 09.02.2023 | Language: | KO | [2023/06] | Type: | A1 Application with search report | No.: | EP4382135 | Date: | 12.06.2024 | Language: | EN | [2024/24] | Search report(s) | International search report - published on: | KR | 09.02.2023 | Classification | IPC: | A61K48/00, A61K31/7105, A61P35/00, C12N15/113 | [2024/24] | CPC: |
A61K48/005 (EP);
A61P35/00 (EP);
C12N15/113 (EP);
C12N2710/10343 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/24] | Title | German: | KREBSSPEZIFISCHES TRANSSPLEISSENDES RIBOZYM ALS GENTHERAPIEPRODUKT IN KOMBINATION MIT STRAHLENTHERAPIE | [2024/24] | English: | CANCER-SPECIFIC TRANS-SPLICING RIBOZYME AS GENE THERAPY PRODUCT COMBINED WITH RADIOTHERAPY | [2024/24] | French: | RIBOZYME DE TRANS-ÉPISSAGE SPÉCIFIQUE AU CANCER EN TANT QUE PRODUIT DE THÉRAPIE GÉNIQUE COMBINÉ À UNE RADIOTHÉRAPIE | [2024/24] | Entry into regional phase | 06.03.2024 | Translation filed | 06.03.2024 | National basic fee paid | 06.03.2024 | Search fee paid | 06.03.2024 | Designation fee(s) paid | 06.03.2024 | Examination fee paid | Examination procedure | 06.03.2024 | Examination requested [2024/24] | Fees paid | Renewal fee | 27.08.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2015194853 (KOREA ATOMIC ENERGY RES [KR]); | [DA]KR20160038674 (UNIV DANKOOK IACF [KR]); | [A]KR20190007488 (REGENERON PHARMA [US]); | [Y]KR20200102943 (RZNOMICS INC [KR], et al); | [A]KR102195221B (SEOUL NAT UNIV R&DB FOUNDATION [KR]); | by applicant | KR20160038674 |